Shandong Buchang Pharmaceuticals Co., Ltd.

SHSE:603858 Stock Report

Market Cap: CN¥16.8b

Shandong Buchang Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Shandong Buchang Pharmaceuticals's earnings have been declining at an average annual rate of -49.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 3.6% per year.

Key information

-49.8%

Earnings growth rate

-49.7%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-3.6%
Return on equity-4.3%
Net Margin-2.5%
Next Earnings Update26 Apr 2025

Recent past performance updates

Recent updates

Does Shandong Buchang Pharmaceuticals (SHSE:603858) Have A Healthy Balance Sheet?

Dec 31
Does Shandong Buchang Pharmaceuticals (SHSE:603858) Have A Healthy Balance Sheet?

Investors Aren't Buying Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues

Dec 04
Investors Aren't Buying Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues

The Market Doesn't Like What It Sees From Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues Yet

Aug 26
The Market Doesn't Like What It Sees From Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues Yet

Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

Jul 29
Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

Why Investors Shouldn't Be Surprised By Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Low P/S

Apr 27
Why Investors Shouldn't Be Surprised By Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Low P/S

We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

Feb 28
We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

Revenue & Expenses Breakdown

How Shandong Buchang Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:603858 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411,776-2935,726364
30 Jun 2411,719-1965,973357
31 Mar 2412,371-226,679344
31 Dec 2313,2453197,373335
30 Sep 2313,630-1,8717,825199
30 Jun 2314,811-1,6028,467285
31 Mar 2315,266-1,5048,471275
31 Dec 2214,951-1,5308,391284
30 Sep 2215,6901,2828,921384
30 Jun 2215,4751,1628,871337
31 Mar 2215,6121,3139,254377
31 Dec 2115,7631,2899,252409
30 Sep 2116,1401,7399,117540
30 Jun 2116,3571,9059,289531
31 Mar 2116,7181,9629,514563
31 Dec 2016,0071,8619,213533
30 Sep 2015,2571,9938,851578
30 Jun 2014,8862,0498,775563
31 Mar 2014,0111,9668,513496
31 Dec 1914,2551,9468,864505
30 Sep 1914,6212,0229,297311
30 Jun 1914,3221,9869,138392
31 Mar 1914,1171,9669,049448
31 Dec 1813,6651,8888,735480
30 Sep 1813,7051,7248,958601
30 Jun 1813,8601,6618,879694
31 Mar 1813,8661,6228,868579
01 Jan 1813,8641,6388,925489
30 Sep 1712,7641,6418,276239
30 Jun 1712,9221,8428,4200
31 Mar 1712,7481,7998,2090
31 Dec 1612,3211,7697,9760
30 Sep 1612,8831,9038,0820
31 Dec 1511,6563,5377,2840
31 Dec 1410,3341,3246,4650

Quality Earnings: 603858 is currently unprofitable.

Growing Profit Margin: 603858 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603858 is unprofitable, and losses have increased over the past 5 years at a rate of 49.8% per year.

Accelerating Growth: Unable to compare 603858's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 603858 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).


Return on Equity

High ROE: 603858 has a negative Return on Equity (-4.27%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 20:39
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shandong Buchang Pharmaceuticals Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiaxi XuIndustrial Securities Co. Ltd.